Source 1review2009Immunological Reviews
Toolkit/CTLA-4Ig
CTLA-4Ig
Also known as: abatacept
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
CTLA-4Ig (abatacept) is now an US Food and Drug Administration (FDA)-approved therapy for rheumatoid arthritis.
Usefulness & Problems
Why this is useful
CTLA-4Ig is described as a therapeutic approach that modulates the B7:CD28/CTLA-4 costimulatory pathway. The review cites it as an FDA-approved therapy for rheumatoid arthritis.; therapeutic modulation of costimulatory pathways; clinical inhibition of the B7:CD28/CTLA-4 axis in autoimmunity
Source:
CTLA-4Ig is described as a therapeutic approach that modulates the B7:CD28/CTLA-4 costimulatory pathway. The review cites it as an FDA-approved therapy for rheumatoid arthritis.
Source:
therapeutic modulation of costimulatory pathways
Source:
clinical inhibition of the B7:CD28/CTLA-4 axis in autoimmunity
Problem solved
It addresses pathogenic immune activation in autoimmunity through costimulatory pathway modulation.; translates costimulatory pathway modulation into an approved therapy for rheumatoid arthritis
Source:
It addresses pathogenic immune activation in autoimmunity through costimulatory pathway modulation.
Source:
translates costimulatory pathway modulation into an approved therapy for rheumatoid arthritis
Problem links
translates costimulatory pathway modulation into an approved therapy for rheumatoid arthritis
LiteratureIt addresses pathogenic immune activation in autoimmunity through costimulatory pathway modulation.
Source:
It addresses pathogenic immune activation in autoimmunity through costimulatory pathway modulation.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
translationInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
Its use requires clinical therapeutic deployment in patients and depends on targeting the B7:CD28/CTLA-4 pathway.; requires therapeutic targeting of the B7:CD28/CTLA-4 pathway in a clinical context
The review does not present it as a universal solution, and emphasizes the challenge of avoiding impaired antimicrobial immunity or increased cancer susceptibility during immune intervention.; the review frames a broader challenge of balancing suppression of pathogenic T-cell responses without compromising antimicrobial immunity or increasing cancer susceptibility
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Dynamic imaging studies indicate that CD28 colocalizes with TCRs in microclusters, recruits PKCθ to TCR-CD28 microclusters, and helps sustain early T-cell activation signals.
CTLA-4Ig (abatacept) is an FDA-approved therapy for rheumatoid arthritis, illustrating successful clinical translation of costimulatory pathway modulation.
PD-1 or PD-L1 blockade can restore immune function in exhausted T cells and has motivated therapeutic strategies for chronic viral infections and cancer.
Approval Evidence
1 source1 linked approval claimfirst-pass slug ctla-4ig
CTLA-4Ig (abatacept) is now an US Food and Drug Administration (FDA)-approved therapy for rheumatoid arthritis.
Source:
therapeutic summarysupports
CTLA-4Ig (abatacept) is an FDA-approved therapy for rheumatoid arthritis, illustrating successful clinical translation of costimulatory pathway modulation.
Source:
Comparisons
Source-stated alternatives
The review also discusses agonistic CD40, 4-1BB, or OX40 antibodies and blockade of CTLA-4 or PD-1 in other therapeutic settings.
Source:
The review also discusses agonistic CD40, 4-1BB, or OX40 antibodies and blockade of CTLA-4 or PD-1 in other therapeutic settings.
Source-backed strengths
presented as a realized clinical translation of preclinical costimulation studies
Source:
presented as a realized clinical translation of preclinical costimulation studies
Compared with cell-free biosensors
CTLA-4Ig and cell-free biosensors address a similar problem space because they share translation.
Shared frame: same top-level item type; shared target processes: translation; shared mechanisms: translation_control; same primary input modality: chemical
Compared with nanofiber scaffold
CTLA-4Ig and nanofiber scaffold address a similar problem space because they share translation.
Shared frame: same top-level item type; shared target processes: translation; shared mechanisms: translation_control; same primary input modality: chemical
Compared with PROTAC
CTLA-4Ig and PROTAC address a similar problem space because they share translation.
Shared frame: same top-level item type; shared target processes: translation; shared mechanisms: translation_control; same primary input modality: chemical
Ranked Citations
- 1.